Entera Bio Ltd. Investments Change (Net)

Investments Change (Net) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Investments Change (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Investments Change (Net) for the quarter ending December 30, 2019 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Investments Change (Net) decreased by -100.0%
  • Annual Investments Change (Net) for 2019 was $4 Million (a -200.0% decrease from previous year)
  • Twelve month Investments Change (Net) ending December 30, 2019 was $0 (a NaN% decrease compared to previous quarter)
Trailing Investments Change (Net) for the last four month:
30 Dec '19 29 Sep '19
$0 $0
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Investments Change (Net) of Entera Bio Ltd.

Most recent Investments Change (Net)of ENTX including historical data for past 10 years.

Interactive Chart of Investments Change (Net) of Entera Bio Ltd.

Entera Bio Ltd. Investments Change (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $0.0 $0.0 $4.0 $4.0
2018 $-4.0 $-4.0
2017 $0.0

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.